Heterogeneity in Prescription Opioid Pain Reliever Misuse Across Age Groups: 2015–2017 National Survey on Drug Use and Health
Prescription opioid misuse among older adults has received little attention to date. Potential age variation in characteristics of and motivations for prescription opioid misuse has not been fully characterized yet has important implications for preventing diversion and misuse.
To examine (1) age-specific patterns of source of misused prescription opioid pain relievers and motives for misuse and (2) age-specific and source-specific associations with opioid use disorder (OUD), heroin use, benzodiazepine misuse, and OUD treatment utilization.
Cross-sectional study using 3 waves (2015–2017) of the National Survey on Drug Use and Health (68% average response rate)
Respondents aged 12 and older with past-year prescription opioid pain reliever misuse (n = 8228)
Source for the most-recently misused prescription pain reliever (categorized as medical, social, or illicit/other), motive for last episode of misuse, OUD, heroin use, benzodiazepine misuse, and OUD treatment.
Adults 50 and older comprised approximately 25% of all individuals reporting past-year prescription opioid misuse. A social source was most common for individuals under age 50 while a medical source was most common for individuals 50 and older. The most commonly reported motive for misuse was to “relieve physical pain”; the frequency of this response increased across age groups (47% aged 12–17 to 87% aged 65+). Among adults age 50 and older with prescription opioid misuse, 17% met criteria for OUD, 15% reported past-year benzodiazepine misuse, and 3% reported past-year heroin use.
Physicians continue to be a direct source of prescription opioids for misuse, particularly for older adults. Ongoing clinical initiatives regarding optimal opioid prescribing practices are needed in addition to effective non-opioid strategies for pain management. Clinical initiatives should also include screening adult and adolescent patients for non-medical use of prescription opioids as well as improving access to OUD treatment for individuals of all ages.
KEY WORDSprescription pain reliever opioid misuse OUD treatment diversion medical source age heterogeneity
This work was funded by awards R01 DA045800 and P50 DA046351.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they do not have a conflict of interest.
The content is solely the responsibility of the authors and does not necessarily represent the official views of NIDA, the NIH, or the US Government.
- 8.Ciccarone D. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019:S0955–3959(19)30018–0.Google Scholar
- 10.CDC WONDER. Multiple cause of death 1999–2017. 2019.Google Scholar
- 24.Šidák ZK. Rectangular confidence regions for the means of multivariate normal distributions. Journal of the American Statistical Association. 1967;62:626–33.Google Scholar
- 39.Evans WN, Lieber E, Power P. How the reformulation of oxycontin ignited the heroin epidemic. National Bureau of Economic Research. 2018;w24475.Google Scholar
- 41.Oldfield BJ, Tetrault JM, Wilkins KM, Edelman EJ, Capurso NA. Opioid overdose prevention education for medical students: adopting harm reduction into mandatory clerkship curricula. Subst Abus. 2019:1–6.Google Scholar
- 48.Reddy UM, Davis JM, Ren Z, Greene MF, Opioid Use in Pregnancy NAS, Childhood Outcomes Workshop Invited S. Opioid use in pregnancy, neonatal abstinence syndrome, and childhood outcomes: executive summary of a joint workshop by the eunice kennedy shriver national institute of child health and human development, American college of obstetricians and gynecologists, American academy of pediatrics, society for maternal-fetal medicine, centers for disease control and prevention, and the march of dimes foundation. Obstet Gynecol. 2017;130:10–28.PubMedPubMedCentralCrossRefGoogle Scholar
- 50.U.S. Preventive Services Task Force. Draft evidence review: illicit drug use, including nonmedical use of prescription drugs: screening. 2019.Google Scholar